Article cité par

La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).

Article cité :

Système de surveillance en addictovigilance : quelles données pharmacoépidémiologiques à l’échelle de l’Europe ?

Maryse Lapeyre-Mestre, Mathilde Dupui

Therapie, 70 2 (2015) 147-156

Publié en ligne : 2015-04-09

DOI: https://doi.org/10.2515/therapie/2015006

Citations de cet article :

Addictovigilance: The Edge of reason?

Maryse Lapeyre-Mestre, Joelle Micallef, Amélie Daveluy, Reynald Le Boisselier, Célian Bertin, Nathalie Fouilhe Sam-Lai, Régis Bordet, Alexandra Boucher, Joëlle Micallef, Hélène Peyrière, Pierre Gillet, Caroline Victorri-Vigneau, Anne Batisse, Marie-Christine Perault-Pochat and Maryse Lapeyre-Mestre
Therapies 80 (2) 155 (2025)
https://doi.org/10.1016/j.therap.2025.01.001

Pregabalin Qualitative Detection in Turkish Forensic Cases Between 2017 to 2018

Ceyda Teker, Rukiye Aslan, Cahit İpekçi, Mehmet Tokdemir and Serap Annette Akgür
Journal of Psychoactive Drugs 56 (3) 380 (2024)
https://doi.org/10.1080/02791072.2023.2226138

Community Pharmacists’ Perceptions towards the Misuse and Abuse of Pregabalin: A Cross-Sectional Study from Aseer Region, Saudi Arabia

Sultan M. Alshahrani, Khalid Orayj, Ali M. Alqahtani and Mubarak A. Algahtany
Healthcare 9 (10) 1281 (2021)
https://doi.org/10.3390/healthcare9101281

Unintentional exposure to pregabalin in ≤6-year-old children: a nationwide French Poison Control Center study

Laurène Dufayet, Fleur Monnet, Hervé Laborde-Casterot, et al.
Clinical Toxicology 59 (5) 433 (2021)
https://doi.org/10.1080/15563650.2020.1822530

Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Maryse Lapeyre-Mestre, Alexandra Boucher, Amélie Daveluy, et al.
Therapies 75 (4) 343 (2020)
https://doi.org/10.1016/j.therap.2020.06.006

Obtention illégale de prégabaline comme proxy de l’usage non médical : analyse nationale multisource du Réseau Français d’Addictovigilance

Joëlle Micallef, Thomas Soeiro, Camille Ponté, et al.
Toxicologie Analytique et Clinique 32 (4) S36 (2020)
https://doi.org/10.1016/j.toxac.2020.09.073

Détection des signaux du réseau français d’addictovigilance : méthodes innovantes d’investigation, illustrations et utilité pour la santé publique

Joëlle Micallef, Émilie Jouanjus, Michel Mallaret and Maryse Lapeyre Mestre
Therapies 74 (6) 579 (2019)
https://doi.org/10.1016/j.therap.2019.09.005

Patterns of gabapentin and pregabalin use and misuse: Results of a population‐based cohort study in France

Damien Driot, Emilie Jouanjus, Stéphane Oustric, Julie Dupouy and Maryse Lapeyre‐Mestre
British Journal of Clinical Pharmacology 85 (6) 1260 (2019)
https://doi.org/10.1111/bcp.13892

Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital

Margaux Lafaurie, Liselotte Pochard, Clémence Lotiron, et al.
Clinical Drug Investigation 38 (10) 977 (2018)
https://doi.org/10.1007/s40261-018-0679-4

Dispositif pharmacoépidémiologique de surveillance des substances psychoactives : intérêts du programme national OPPIDUM du Réseau français d’addictovigilance

Elisabeth Frauger, Liselotte Pochard, Quentin Boucherie, et al.
Therapies 72 (4) 491 (2017)
https://doi.org/10.1016/j.therap.2017.01.010

Changes over time in prescription practices of pain medications in Switzerland between 2006 and 2013: an analysis of insurance claims

Maria M. Wertli, Oliver Reich, Andri Signorell, et al.
BMC Health Services Research 17 (1) (2017)
https://doi.org/10.1186/s12913-017-2086-6

Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals

Luca Passamonti, M. Luijten, H. Ziauddeen, et al.
Psychopharmacology 234 (15) 2289 (2017)
https://doi.org/10.1007/s00213-017-4643-4

Which psychoactive substances are used by patients seen in the healthcare system in French overseas territories? Results of the OPPIDUM survey

Amélie Daveluy, Elisabeth Frauger, Hélène Peyrière, Christophe Moracchini, Françoise Haramburu and Joëlle Micallef
Fundamental & Clinical Pharmacology 31 (1) 126 (2017)
https://doi.org/10.1111/fcp.12233

Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement

Maximilian Gahr, Bernhard Connemann, Carlos Schönfeldt-Lecuona and René Zeiss
International Journal of Molecular Sciences 18 (1) 101 (2017)
https://doi.org/10.3390/ijms18010101

Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter"

Emilie Jouanjus, Michel Mallaret, Joëlle Micallef, et al.
Drug Safety 40 (2) 183 (2017)
https://doi.org/10.1007/s40264-016-0497-7

Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database

Jean-Baptiste Bossard, Camille Ponté, Julie Dupouy, Maryse Lapeyre-Mestre and Emilie Jouanjus
Clinical Drug Investigation 36 (9) 735 (2016)
https://doi.org/10.1007/s40261-016-0421-z